AstraZeneca Pharma India Limited

BSE:506820 Stock Report

Market Cap: ₹159.5b

AstraZeneca Pharma India Past Earnings Performance

Past criteria checks 1/6

AstraZeneca Pharma India has been growing earnings at an average annual rate of 13.1%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 12.3% per year. AstraZeneca Pharma India's return on equity is 12.1%, and it has net margins of 5.5%.

Key information

13.1%

Earnings growth rate

13.1%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate12.3%
Return on equity12.1%
Net Margin5.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How AstraZeneca Pharma India makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:506820 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2414,8458192,6020
30 Jun 2413,8769592,4960
31 Mar 2412,9551,6152,4740
31 Dec 2311,9701,3932,7090
30 Sep 2311,4101,5282,6330
30 Jun 2310,6611,3302,5670
31 Mar 2310,0309932,6080
31 Dec 229,5021,1002,6470
30 Sep 229,0099212,5520
30 Jun 228,6257152,4830
31 Mar 228,0566162,3450
31 Dec 217,8396092,2790
30 Sep 217,8367052,2310
30 Jun 217,9548492,2360
31 Mar 218,1369332,2270
31 Dec 207,9827562,2450
30 Sep 208,2188132,1960
30 Jun 208,2086932,1760
31 Mar 208,3187222,1960
31 Dec 198,2727252,0700
30 Sep 198,1857492,1040
30 Jun 197,7146961,9980
31 Mar 197,2835452,0610
31 Dec 186,8874781,9560
30 Sep 186,021831,8870
30 Jun 186,0502651,8370
31 Mar 185,7102591,5570
31 Dec 175,3191751,4930
30 Sep 175,5364421,4390
30 Jun 175,2751762,1050
31 Mar 175,4372011,5870
31 Dec 165,8662791,8180
30 Sep 165,8092061,7770
30 Jun 165,7111311,7320
31 Mar 165,637531,7680
31 Dec 155,5294282,8920
30 Sep 155,1662072,9340
30 Jun 154,753-51,5460
31 Mar 154,690-2081,7150
31 Dec 144,624-6152,948103
30 Sep 144,732-4662,906103
30 Jun 144,742-1991,7020
31 Mar 144,737-52,773103
31 Dec 134,545-1652,555164

Quality Earnings: 506820 has a high level of non-cash earnings.

Growing Profit Margin: 506820's current net profit margins (5.5%) are lower than last year (13.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 506820's earnings have grown by 13.1% per year over the past 5 years.

Accelerating Growth: 506820's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 506820 had negative earnings growth (-46.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.4%).

Return on Equity

High ROE: 506820's Return on Equity (12.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 20:03
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AstraZeneca Pharma India Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kameswari V. S. ChavaliFirstCall Research